These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 2260040)
21. Rhode Island physicians' recognition and reporting of adverse drug reactions. Scott HD; Rosenbaum SE; Waters WJ; Colt AM; Andrews LG; Juergens JP; Faich GA R I Med J (1976); 1987 Jul; 70(7):311-6. PubMed ID: 3476980 [No Abstract] [Full Text] [Related]
22. Post marketing surveillance of new drugs. Patient safety in the hands of GPs. Marley JE Aust Fam Physician; 1989 Sep; 18(9):1133-5. PubMed ID: 2590077 [TBL] [Abstract][Full Text] [Related]
23. [How to assess the risk of drugs?]. Roujeau JC Ann Dermatol Venereol; 1998 Oct; 125(10):673-5. PubMed ID: 9835953 [No Abstract] [Full Text] [Related]
24. The diagnosis of adverse medical events associated with drug treatment. Stephens MD Adverse Drug React Acute Poisoning Rev; 1987; 6(1):1-35. PubMed ID: 3303863 [No Abstract] [Full Text] [Related]
25. An adverse drug reaction reporting program. Wasan SM; Marshall LB Can J Hosp Pharm; 1989 Dec; 42(6):239-41. PubMed ID: 10318356 [No Abstract] [Full Text] [Related]
26. Critical reflection on the collection and evaluation of adverse drug reaction data. Venulet J Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S48-53. PubMed ID: 3842691 [No Abstract] [Full Text] [Related]
27. Current French system of post-marketing drug surveillance. Albengres E; Gauthier F; Tillement JP Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):312-4. PubMed ID: 2387656 [TBL] [Abstract][Full Text] [Related]
28. Program for improving adverse drug reaction reporting. Chatas CA; Vinson BE Am J Hosp Pharm; 1990 Jan; 47(1):155-7. PubMed ID: 2301425 [No Abstract] [Full Text] [Related]
30. [Critical analysis of the adverse effects reported to the Paris-Fernand Widal Drug Monitoring Center in a 2-month period]. Castot A; Carlier P; Lagier G; Elmalem J; Vincens M; Efthymiou M Therapie; 1986; 41(5):375-7. PubMed ID: 3810528 [No Abstract] [Full Text] [Related]
31. Strategy for surveillance of adverse drug events. Bright RA Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403 [No Abstract] [Full Text] [Related]
32. Active reporting scheme: an example to evaluate specific adverse drug reactions. Pini LA; Sternieri E Acta Physiol Hung; 1990; 75 Suppl():237-8. PubMed ID: 2371875 [No Abstract] [Full Text] [Related]
33. [Surveillance studies criticized. A marketing effort for expensive drugs? "Not throwing the baby out with the bath water" (interview by Dr. Beate Schumacher)]. Selbmann HK MMW Fortschr Med; 2009 Aug; 151(34-35):6. PubMed ID: 19771776 [No Abstract] [Full Text] [Related]
34. ["There are clear criteria for product surveillance studies"]. Throm S MMW Fortschr Med; 2009 Aug; 151(34-35):7. PubMed ID: 19771777 [No Abstract] [Full Text] [Related]
35. [Responsibility of the pharmaceutical industry toward the first undesirable effects of new products]. Juillet Y; de Cremiers F Therapie; 1988; 43(5):385-8. PubMed ID: 3227498 [No Abstract] [Full Text] [Related]
37. Early postmarketing drug safety surveillance: data mining points to consider. Hauben M Ann Pharmacother; 2004 Oct; 38(10):1625-30. PubMed ID: 15304626 [TBL] [Abstract][Full Text] [Related]
38. Should new drugs be avoided? Child Health Alert; 2002 Jun; 20():2. PubMed ID: 12096722 [No Abstract] [Full Text] [Related]
39. [Regulatory guidelines and drug safety]. Flury W Ther Umsch; 1993 Jan; 50(1):49-51. PubMed ID: 8378867 [TBL] [Abstract][Full Text] [Related]
40. Statewide test of a new postmarketing drug surveillance system. Fisher S; Bryant SG; Solovitz BL; Kluge RM Tex Med; 1987 Aug; 83(8):59-62. PubMed ID: 3660262 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]